Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 2

2(25.0%)

Early Phase 1

1(12.5%)

Phase 4

1(12.5%)

8Total

Phase 1(4)

Phase 2(2)

Early Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05393193Phase 4Active Not Recruiting

POC HIV Testing and Early DTG Use for Infants

Role: collaborator

NCT02369406Phase 2Active Not Recruiting

Early Infant HIV Treatment in Botswana

Role: collaborator

NCT03526848Phase 1Completed

3BNC117 and 10-1074 in ART-treated Individuals

Role: collaborator

NCT06135974Early Phase 1Completed

Vaginal lIve Biotherapeutic RANdomized Trial

Role: collaborator

NCT03307915Phase 1Completed

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Role: collaborator

NCT02431325Phase 2Completed

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

Role: collaborator

NCT03205917Phase 1Completed

A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults

Role: collaborator

NCT02445079Completed

Ugandan Non-Communicable Diseases and Aging Cohort

Role: collaborator

NCT01215149Phase 1Completed

Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults

Role: collaborator

All 9 trials loaded